Key Points
-
The sphingolipids constitute an important class of bioactive lipids, including ceramide and sphingosine-1-phosphate (S1P). Ceramide can be considered to function as a hub in sphingolipid metabolism, and it mediates or regulates antiproliferative responses such as growth inhibition, apoptosis, differentiation and senescence, whereas S1P is a key regulator of cell motility and proliferation.
-
The study of bioactive lipids in general and sphingolipids in particular presents several hurdles to molecular cell biologists. These include the hydrophobicity and biophysical properties of these molecules, the metabolic interconnections of the active metabolites, and the predominantly hydrophobic nature of the enzymes that regulate their metabolism.
-
Enzymes of sphingolipid metabolism function as an interconnected network that regulates the levels and interconversions of the bioactive sphingolipids. Many of these enzymes, such as sphingomyelinases, sphingosine kinases and ceramide synthases, serve to couple the action of extra- and intracellular agonists to downstream effectors.
-
Ceramide can be formed from the de novo pathway or following activation of the sphingomyelinase pathway, in which it functions in metabolic regulation and stress responses. Ceramide action is governed by the specific pathways that regulate its formation, their subcellular localization and their specific mechanisms of regulation.
-
S1P is a product of sphingosine kinases, and acts predominantly on a family of G protein-coupled receptors that, in turn, mediate its action on cell growth, migration, transcription and signal transduction.
-
The cellular actions of ceramide, S1P and other bioactive sphingolipids are increasingly thought to be crucial for the study of angiogenesis, inflammation, immune responses, diabetes, ageing, cancer biology and degenerative diseases.
Abstract
It has become increasingly difficult to find an area of cell biology in which lipids do not have important, if not key, roles as signalling and regulatory molecules. The rapidly expanding field of bioactive lipids is exemplified by many sphingolipids, such as ceramide, sphingosine, sphingosine-1-phosphate (S1P), ceramide-1-phosphate and lyso-sphingomyelin, which have roles in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking. Deciphering the mechanisms of these varied cell functions necessitates an understanding of the complex pathways of sphingolipid metabolism and the mechanisms that regulate lipid generation and lipid action.
Similar content being viewed by others
Main
Although the concept of 'bioactive lipids' — broadly defined as changes in lipid levels that result in functional consequences — has been decades in the making, it has only started to gain traction in the past 20 years, and promises to occupy centre-stage in cell biology research in the twenty-first century. This belated recognition has its roots in earlier preconceived ideas about exclusive roles for lipids in energy metabolism and in membrane structure, which have prevented wider thinking about functional lipids by non-lipidologists. These impediments primarily arise from the many inherent difficulties of working with lipids, their enzymes and their targets.
In their pioneering studies in the 1950s, Hokin and Hokin observed the rapid turnover of inositol phospholipids in pancreatic slices that were stimulated with acetylcholine1. However, the significance of those observations for cell function lay relatively dormant for several years until diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) were subsequently implicated in specifically regulating protein kinase C (PKC) and calcium release2, respectively, leading to various cellular responses. Conceptually, the demonstration of direct activation of PKC by the lipid DAG cemented the idea that a lipid (which already had an established role in intermediary metabolism) could regulate cell signalling, and ushered in the era of bioactive lipids.
Studies over the past four decades have also defined the eicosanoids (and other products of arachidonic acid metabolism) as key inter- and intracellular lipid signalling molecules, which are primarily involved in mediating or resolving inflammatory responses3. Further studies have shown that many minor products of inositol phospholipid metabolism, such as phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3), also serve as key intermediates in cell signalling. Other glycerolipid-derived regulatory molecules include phosphatidic acid (PA), monoacylglycerols and anandamide (candidate ligands for cannabinoid receptors), lyso-phosphatidic acid and platelet activating factor (PAF).
Another group of bioactive lipids that have come to the foreground in the past two decades are the sphingolipids. The first of these to be identified was sphingosine, which exerts pleiotropic effects on protein kinases and other targets. Sphingosine and its related sphingoid bases have roles in regulating the actin cytoskeleton, endocytosis, the cell cycle and apoptosis4 (Fig. 1). Even more emphasis has been placed on the sphingolipids ceramide and sphingosine-1-phosphate (S1P). Ceramide mediates many cell-stress responses, including the regulation of apoptosis5 and cell senescence6, whereas S1P has crucial roles in cell survival, cell migration and inflammation7 (Fig. 1). Recent additions to the family of bioactive sphingolipids include ceramide-1-phosphate (C1P, which has roles in inflammation and vesicular trafficking8,9,10), glucosylceramide (which is involved in post-Golgi trafficking and in drug resistance11,12), lyso-sphingomyelin and dihydroceramide.
In addition to the vast number of cellular processes that sphingolipids are associated with, further levels of complexity in sphingolipid signalling are only now being deciphered. This complexity arises from the metabolic interconnection of bioactive lipids (Fig. 2), with changes in one lipid exerting metabolic 'ripple' effects with functional consequences. Moreover, the enzymes of lipid metabolism (the input into these pathways) are often hydrophobic membrane proteins that defy simple biochemical and cellular investigation. The varied biophysical properties of the regulatory lipids also introduce complications concerning their subcellular localization and mechanisms of action.
Therefore, a comprehensive understanding of bioactive sphingolipids (and other lipids in general) requires at least two levels of investigation. At a basic level, there is a need to delineate the various specific mechanisms by which sphingolipid metabolism is regulated and the molecular mechanisms by which the bioactive lipid products transmit their respective signals. At an advanced and lipid-specific level, such an understanding requires knowledge of the metabolic organization of enzymes of sphingolipid metabolism and their inter-relationships, the subcellular and submembranous localization of lipid-mediated pathways, the metabolic transformation of bioactive lipids, and the integration or coordination of overall responses. This review aims to inform the reader about the basic organization and principles of sphingolipid-mediated cell regulation, and to provide a current understanding about specific sphingolipid signalling pathways. In the process, we attempt to elucidate principles that govern the operation of bioactive lipids in general.
Introducing the sphingolipid family
Sphingolipid metabolism mainly occurs in eukaryotes, but is also found in the Sphingomonas bacterial genus. Pathways of sphingolipid metabolism have a unique metabolic entry point (serine palmitoyl transferase; SPT), which forms the first sphingolipid in the de novo pathway, and a unique exit point, S1P lyase, which breaks down S1P into non-sphingolipid molecules. The multiple metabolic steps in between constitute a highly complex network that connects the metabolism of many sphingolipids (Fig. 2). In this network, ceramide (and dihydroceramide to a lesser degree) can be considered to be a metabolic hub because it occupies a central position in sphingolipid biosynthesis and catabolism.
Briefly, sphingolipids are synthesized de novo from serine and palmitate, which condense to form 3-keto-dihydrosphingosine through the action of SPT13,14. In turn, 3-keto-dihydrosphingosine is reduced to dihydrosphingosine, followed by acylation by a (dihydro)-ceramide synthase (also known as Lass or CerS)15. Ceramide is formed by the desaturation of dihydroceramide16 (Fig. 2).
In sphingolipid biosynthetic pathways (Fig. 2), ceramide can be phosphorylated by ceramide kinase17, glycosylated by glucosyl or galactosyl ceramide synthases18, or can receive a phosphocholine headgroup from phosphatidylcholine (PC) in the biosynthesis of sphingomyelin (SM) through the action of SM synthases19, which thereby also serve to generate DAG from PC.
Breakdown of complex sphingolipids (Fig. 2) proceeds through the action of specific hydrolases, leading to the formation of glucosylceramide and galactosylceramide. In turn, specific β-glucosidases and galactosidases hydrolyse these lipids to regenerate ceramide20,21. The breakdown of SM is catalysed by one of several sphingomyelinases (SMases)22. These include acid SMase, neutral SMases and alkaline SMase.
Ceramide may be broken down by one of many ceramidases23,24, leading to the formation of sphingosine, which seems to have one of two fates. Sphingosine may be 'salvaged' or recycled into sphingolipid pathways (Box 1), or it can be phosphorylated by one of two sphingosine kinases25, SK1 and SK2 (Fig. 2). The product S1P can be dephosphorylated to regenerate sphingosine through the action of specific intracellular S1P phosphatases26 and, possibly, non-specific extracellular lipid phosphate phosphatases27,28. Alternatively, S1P lyase can irreversibly cleave S1P to generate ethanolamine phosphate and hexadecenal (which, in turn, can be reduced to palmitate and subsequently reincorporated into lipid metabolic pathways)29.
Complexities of sphingolipid signalling
The conceptualization of cell signalling is largely dominated by the canonical cyclic AMP paradigm, whereby a linear signalling pathway exists that involves receptors, cyclase, cAMP and cAMP-dependent protein kinase, and in which cAMP has a dedicated signalling function. However, sphingolipid signalling manifests additional layers of complexity compared with the cAMP pathway. Unlike the relative simplicity of the biochemically isolated cAMP pathway, enzymes of lipid metabolism are intimately related to each other, generating an interconnected network (Fig. 2) that serves to regulate not only the levels of individual bioactive lipids, but also their metabolic interconversion. Moreover, there are multiple pathways that can operate in parallel (Fig. 3). Also, unlike the soluble cAMP molecule, bioactive sphingolipids exhibit hydrophobic properties; therefore, the physiological environment of bioactive lipids is, for the most part, restricted to biological membranes. So, a crucial and unique set of properties operates in the cell to define the subcellular localization of sphingolipid-mediated pathways and the transport of bioactive lipids across and between membranes. These complexities are discussed below.
The interconnectivity of sphingolipid metabolism. The unprecedented complexity in sphingolipid biochemical interconnections enables cells to orchestrate cellular responses by regulating sphingolipid interconversions. For example, activation of SMase generates ceramide as an immediate lipid product. However, the subsequent action of ceramidase, ceramide kinase, SM synthase or glucosylceramide synthase may potentially convert the ceramide signal to one that is mediated by sphingosine (and subsequently S1P), C1P, DAG or glucosylceramide, respectively (Fig. 2).
Interestingly, the cellular levels of these bioactive sphingolipids render these scenarios highly likely30. For example, in most cell types, SM is present in concentrations that are an order of magnitude higher than those of ceramide; therefore, small changes in SM can result in profound changes in ceramide. In addition, ceramide is often detected in concentrations that are more than an order of magnitude higher than those of sphingosine. Therefore, immediate hydrolysis of only 3–10% of newly generated ceramide may double the levels of sphingosine. Similarly, phosphorylation of 1–3% sphingosine may double the levels of S1P (Fig. 1).
Given these metabolic considerations, it is possible that when a sphingolipid enzyme is implicated in a process, the direct product of this enzyme may not be the actual signalling effector. Therefore, it is important to determine which lipid product or substrate actually mediates the signal. For example, by implicating SMase or SKs in a specific cell response, one may not immediately conclude that it is ceramide or S1P that directly mediates such function. Fortunately, tools and approaches are now available to tease these processes out. These include highly sensitive mass spectrometry methods for sphingolipid analysis30,31, molecular tools that have been generated by the nearly complete molecular identification of all known enzymes of sphingolipid metabolism, and RNA interference, which has been applied successfully to cell biology studies of lipid metabolism and function.
Parallel networks of sphingolipid signalling. The multiplicity of several of the pathways of sphingolipid metabolism generates another layer of complexity, which is superimposed on the basic blueprint of sphingolipid metabolism discussed above. This is best illustrated with the ceramide synthases15 (Fig. 3). Six individual ceramide synthases are now known to catalyse the formation of dihydroceramides or ceramides (depending on whether the substrate is dihydrosphingosine or sphingosine, respectively). Importantly, these ceramide synthases show distinct preferences for the different fatty acyl-CoA substrates and, therefore, they generate distinct ceramides with unique N-linked fatty acids. Distinct ceramides may localize to distinct subcompartments and may mediate distinct functions. As another example, both acid SMase and neutral SMase can act on SM to generate ceramide. However, these two enzymes are regulated differentially, localize to distinct subcellular compartments (Box 1) and may even generate ceramides with distinct molecular species.
Subcellular localization of bioactive sphingolipids. Most enzymes of sphingolipid metabolism show specific subcellular localization(s) (Box 1), and this exerts profound effects on the signalling and regulatory functions of the generated sphingolipid. For example, acid SMase localizes primarily to the endolysosomal pathway but, under certain conditions, can also relocate to the plasma membrane, presumably at the outer leaflet32. Neutral SMase2 appears to localize to the inner leaflet of the plasma membrane. SK1 and SK2 seem to act preferentially on a sphingosine substrate that resides in membranes, which requires the translocation of SK enzymes from their cytosolic compartment to the plasma membrane (and other membranes) and binding to anionic lipids33. It is therefore more likely that SK enzymes have multiple subcellular localizations that could dictate distinct functional responses.
These considerations, coupled with the poor solubility of lipids (Box 2) in cells, impose clear restrictions on the subcellular localization of bioactive lipids. In the absence of specific mechanisms of transport for these lipids, the site of generation of a bioactive lipid is likely to dictate its site of action, unless proven otherwise.
Bioactive sphingolipids (and lipids in general) may be divided into separate classes that can be distinguished by their biophysical properties (Box 2). Some bioactive lipids, such as C1P and phosphatidylinositol-3-phosphate, carry ionic charges at neutral pH and contain two hydrophobic chains. These lipids are most likely to reside in their compartment of generation and are unlikely to flip spontaneously across bilayers. A second group, which includes ceramide and DAG, is composed of neutral hydrophobic molecules that are also restricted to their compartments of formation, but may readily flip-flop across membranes34.
A third group is composed of single-chain lipids, and these include sphingosine, S1P, lyso-sphingomyelin and lyso-phosphatidic acid. These molecules have sufficient aqueous solubility to move between membranes. For example, we have estimated that ∼70% of sphingosine resides in membranes at physiological pH and the remaining 30% is soluble35. These molecules can therefore equilibrate quickly among membranes. More importantly, given their amphipathic nature (that is, soluble in both water and organic solvents), these molecules may exert surfactant activity. Therefore, it is not surprising that their cellular levels tend to be among the lowest of all bioactive lipids.
Transport and flipping of bioactive sphingolipids. For bioactive sphingolipids to effect functional responses, they must be able to interact with relevant direct mediators. The subcellular restriction of bioactive sphingolipids and some of their targets poses several questions as to how interacting partners are able to meet (Fig. 4). For example, S1P is probably generated at the inner leaflet of the plasma membrane in response to tumour necrosis factor-a (TNFa) and other agonists36,37. Yet, it appears that it has to reach the outer leaflet of the plasma membrane to interact with S1P receptors (S1PRs)38. Along those lines, two members of the ABC transporter superfamily have been suggested to regulate S1P transport (Fig. 4). The cystic fibrosis transmembrane regulator (CFTR) has been implicated in the internalization of S1P from the plasma membrane39, whereas the ABC transporter ABCC1 has recently been reported to facilitate efflux of S1P40.
The ceramide transfer protein CERT has been shown to effect ceramide transport from its site of synthesis in the endoplasmic reticulum (ER) to the Golgi and to be required for synthesis of SM (but not for glucosylceramide synthesis)41 (Box 1). Given the interaction of CERT with phosphatidylinositol phosphates and its potential regulation by phosphorylation, this step of ceramide metabolism may be regulated by pathways of inositol lipid metabolism, and by protein kinases42 and phosphatases.
As a neutral lipid, ceramide is expected to flip-flop across membranes with ease, and indeed, studies in model membranes and membranes from erythrocytes confirm these predictions34 (Fig. 4). However, it is not clear if the ceramide that forms in more complex biological membranes flips with the same efficiency, or if the organization of ceramide into microdomains (these are specialized lipid domains in the plasma membrane; see the review by van Meer and colleagues in this issue) may restrict flipping of ceramide from the outer leaflet into the inner leaflet. Restricted flipping (or flopping from the inner to outer leaflet) could have immense effects on the signalling functions of ceramide. For example, ceramide that is generated by acid SMase in the outer leaflet may exert distinct functions compared with ceramide that is generated in the inner leaflet by neutral SMase2 (Ref. 22).
In summary, the biophysical and metabolic considerations outlined above introduce a level of complexity that is not seen in other signalling pathways. There are at least 26 distinct enzymes that act on ceramide as either a substrate or product, and which therefore have the potential to regulate ceramide levels. These enzymes show specific and varied subcellular localizations. Moreover, ceramide itself is a family of closely related molecules with at least 50 distinct molecular species that can be distinguished by their acyl chains, hydroxylations and desaturation (Fig. 3). Therefore, ceramide levels may be regulated in distinct compartments by distinct mechanisms at different times. So, asking the question of what ceramide does is not useful, because ceramides that are formed by different mechanisms in distinct compartments, by necessity, exert different functions, and more probing questions should query the specific pathways of ceramide generation.
Mechanisms of action: ceramide and S1P
Understanding what bioactive lipids do and how they transmit signals requires elucidation of the mechanisms by which these lipids act. One could envision two general mechanisms for the action of lipids: lipid–lipid interactions, whereby the candidate bioactive lipid affects membrane structure and/or the interaction of membrane proteins with the membrane bilayer (see the review by van Meer and colleagues in this issue); or lipid–protein interactions, whereby changes in lipids modulate the function of target proteins that interact specifically with the candidate bioactive lipid.
The physiological levels of bioactive lipids clearly influence (or even dictate) their mechanisms of action. Trace lipids such as S1P interact with high-affinity receptors that are capable of sensing their low levels. Lipids that are found at intermediate membrane concentrations, such as ceramide or DAG (which often constitute 0.1–1.0% of total membrane lipids), act on targets with intermediate affinity. By contrast, it is difficult to envisage how abundant lipids such as SM can have specific targets because the affinity of interactions must be low. This does not rule out proteins that may bind to these lipids with high affinity, but in this case, such proteins would not be able to sense changes in the levels of these lipids. The high levels of these lipids, however, impart on them the ability to change overall membrane properties and substructure if and when their levels change. For ceramide and S1P, interest has focused on defining the direct protein targets of action. Several candidate proteins have been shown to interact with ceramide in vitro and in cells (Fig. 5). These include ceramide-activated Ser–Thr phosphatases (CAPPs), such as PP1 and PP2A, which bind ceramide in vitro43. They are modestly activated by ceramide and show a preference for the natural stereoisomers. Studies in cells have linked the action of ceramide to CAPPs and the induction of protein dephosphorylation. For example, ceramide-inducing agents (such as TNFa or loading the cell with palmitate) induce dephosphorylation of the retinoblastoma gene product RB44, PKCα45, protein kinase B (PKB or AKT)46 and other proteins in a ceramide-dependent manner. However, to demonstrate the direct cellular activation of phosphatases by ceramide, experimental evidence is needed (for example, observation of translocation). Defining the specific binding sites of this activation process could result in improved understanding of how these interactions occur and could also provide specific tools for investigating these pathways.
In addition, ceramide has been shown to activate PKCζ47,48, the kinase KSR49 and cathepsin D50. The latter has been proposed as a specific target for lysosomally generated ceramide, and may couple the action of lysosomal acid SMase to the mitochondrial pathway of apoptosis50. Activation of PKCζ by ceramide has been implicated in the regulation of membrane potential, inhibition of AKT and pro-apoptotic functions48,51.
S1P is one of the more soluble sphingolipids and is present in low nanomolar concentrations in the cell (but in high nanomolar concentrations in serum where it is associated with lipoproteins and albumin52). It interacts with S1PRs53, which are high-affinity G protein-coupled receptors (GPCRs) and the only known receptors for S1P that have been identified so far. The five S1PRs (S1PR1–5) display selective tissue expression that is crucial for their biological functions and use well-known GPCR intracellular signalling pathways to mediate their specific effects (Fig. 6). S1P also seems to exert S1PR-independent actions intracellularly, such as induction of calcium release8, although these mechanisms remain unknown. Because an intracellular molecular target for S1P has not been identified, its intracellular role continues to be a subject of speculation and significant interest.
Sphingolipid-mediated cell regulation
Research into bioactive sphingolipids continues to grow at an accelerated pace, with >18,000 PubMed entries to date on ceramide, sphingosine and S1P, mostly related to their signalling functions. As such, a comprehensive discussion of the many facets of these pathways is no longer tenable within the scope of a single review. This section will focus on three specific pathways of ceramide signalling and on the SK1–S1P pathway in inflammation and angiogenesis in order to introduce the key players and provide a glimpse of our current knowledge of sphingolipid-mediated cell regulation.
De novo synthesis of sphingolipids and stress responses. The de novo pathway of sphingolipid biosynthesis, which resides in the ER, has emerged as a key mechanism in eukaryotic cells for regulating the levels of ceramide and other sphingolipids. In mammalian cells, de novo synthesis of ceramide is enhanced in response to some chemotherapeutic agents, such as etoposide and daunorubicin54,55, and other inducers of apoptosis such as stimulation of the B-cell receptor56. The pro-apoptotic FAS pathway stimulates de novo synthesis that has been shown to activate PP1. This results in dephosphorylation of SR proteins, which are regulators of RNA splicing, the function of which is regulated by phosphorylation57. This tilts the balance of pro- and anti-apoptotic mRNAs in favour of the pro-apoptotic caspase-9 and BCL-X57.
Interestingly, the de novo pathway is metabolically geared to respond to changes in serine and palmitate concentrations because SPT displays Km values for the two substrates that are in the range of their usual intracellular concentrations58 (Fig. 1). Indeed, a recent study in yeast demonstrated that heat stress induces an acute influx of serine into the ER that drives de novo synthesis59. Activation of this pathway in yeast results in transient accumulation of sphingoid bases, followed by sphingoid base phosphates and then ceramide. Multiple studies have indicated that sphingoid bases that are generated in this pathway mediate specific responses to heat stress60, which include regulation of nutrient permeases61, cytoskeletal changes62, cell-cycle arrest59 and RNA translation63.
Regulation of de novo synthesis by palmitate may have a key role in diabetes and the metabolic syndrome (Fig. 5a). Emerging evidence suggests that palmitate loading results in the accumulation of ceramide, which activates PP2A and results in dephosphorylation and inactivation of AKT46, a key mediator in insulin signalling and metabolic control. Ceramide may exert additional effects on AKT and on other targets that, together, result in a deterioration in insulin responsiveness and in the death of islet cells64,65 (a process termed lipoptosis) and may contribute to other diabetic complications. A recent study in mice demonstrated that inhibition of ceramide synthesis, either by pharmacological treatments or genetic manipulations, prevented insulin resistance induced by fatty acids, obesity or glucocorticoids65.
Although the significance of this pathway is now appreciated, several key questions remain to be addressed. Increased flux through the de novo pathway does not necessarily lead to ceramide accumulation unless further metabolic transformation (for example, to SM, C1P or glucosylceramide) is limiting or inhibited (as has been shown in some cases of apoptosis in which SM synthase and glucosylceramide synthase (GCS) are suppressed). Also, it is not clear if the de novo pathway acts exclusively in the ER or also in other ER-associated membranes (such as mitochondrial-associated membranes or the nuclear membrane). The location of the de novo pathway could possibly tie it to the regulation of ER stress, but this has yet to be evaluated.
Acid SMase and the salvage pathway in stress signalling. Multiple stress stimuli, such as ultraviolet (UV) and ionizing radiation, ligation of death receptors and chemotherapeutic agents (including platinum, paclitaxel and histone deacetylase inhibitors) have been shown to activate acid SMase, usually within a few minutes of cell stimulation (Fig. 5b). This has been demonstrated primarily by showing increased in vitro activity of the enzyme, and thus is an indication of some post-translational modification of acid SMase. In a few studies, activation of SMase was shown to be accompanied by translocation to the plasma membrane and the simultaneous generation of ceramide66.
Beyond these correlations, several studies have provided more direct evidence for the involvement of acid SMase in ceramide generation and in downstream responses, either through using genetic mutants of the enzyme (obtained from patients with Niemann–Pick disease)67, knockout mice that lack acid SMase68, small interfering (si)RNA-mediated knockdown69 or pharmacological inhibitors70 such as one of the tricyclic amines, desipramine or imipramine. However, such pharmacological studies need to be interpreted with caution because these inhibitors have other targets, including acid ceramidase71. Gene knockout or knockdown studies have now clearly implicated acid SMase in mediating apoptotic and stress responses to ionizing and UV radiation68,72, and to lower concentrations of FAS ligands73. However, other studies have demonstrated increased sensitivity to FAS but reduced mitogenic stimulation of T cells in the knockout mouse74.
The mechanisms that are involved in activation of acid SMase in response to stress agents are poorly defined. Recent results show that the enzyme is activated by reactive oxygen species and, perhaps more specifically, by nitrosative stress75. Other recent studies provided evidence for regulation of acid SMase by phosphorylation in response to activation of PKCδ, and this was implicated in mediating the effects of UV radiation on activation of acid SMase72. These studies are beginning to provide important mechanistic links between stress response pathways that were previously thought to be distinct (acid SMase, nitrosative stress and PKCδ).
Ceramide that is generated by acid SMase has been proposed to reside either in the lysosome or at the plasma membrane (Box 1). Both locations are plausible because acid SMase has been conclusively shown to exist at both subcellular sites. In the lysosome, ceramide has been shown to interact directly with the protease cathepsin D and to activate it, which possibly causes cleavage and activation of the pro-apoptotic protein BID50 (Fig. 5b). At the plasma membrane, the actions of ceramide are less well defined, but have been suggested to mediate receptor capping (microscopic clustering) and/or microdomain formation70.
In an illustration of the complex nature of ceramide metabolism, it was recently shown that activation of acid SMase in response to phorbol esters also leads to a concomitant increase in ceramide formation through the salvage (or recycling) pathway76. In this pathway, sphingosine is recycled to ceramide through the action of ceramide synthases (Box 1). This could explain some of the apparent discrepancies in the literature in which both acid SMase and the de novo pathway (based on inhibition of ceramide synthase by fumonisin B1) have been implicated in several cellular responses (for example, to doxorubicin). Importantly, fumonisin B1 inhibits ceramide synthases and does not distinguish de novo synthesis from recycling (Box 1). Therefore, it could be suggested in these cases that acid SMase is coupled to recycling.
Neutral SMase2 in cytokine action. Multiple studies have coupled activation of neutral SMase to the action of several extracellular cytokines and stress responses77, and the list of inducers shows much overlap with activators of acid SMase. However, progress in the molecular dissection of neutral SMase-mediated pathways only developed following the recent identification of neutral SMase-2 (nSMase2) as a bona fide sphingomyelinase78,79. Importantly, knockout of the enzyme was found to result in short stature, and a natural mutation in nSMase2 (fro/fro mouse) results in bone fragility80,81.
nSMase2 has been implicated in several cell responses. It is acutely activated by the cytokines TNFa and interleukin (IL)-1 and has been shown to mediate the effects of IL-1 on signal transduction (in the phosphorylation of c-Jun N-terminal kinase (JNK))82, and the effects of TNFa on gene induction (involving endothelial nitric oxide synthase (eNOS))83. The enzyme has also been shown to be induced during ageing in mouse hepatocytes and to mediate a decreased responsiveness of hepatocytes to IL-1 signalling84. nSMase2 has been shown to mediate, at least in part, the effects of TNFa on cell adhesion and migration85.
Several studies have implicated nSMase2 in the cytotoxic action of amyloid peptide-β, demonstrating attenuation of these responses in cells in which nSMase2 was knocked down with siRNA86,87. Long-term induction of the enzyme has been observed upon cell confluence (the enzyme was initially cloned as the cell confluence-associated (CCA) gene88) and has been implicated in mediating cell-cycle arrest that is induced by cell contact89.
The mechanisms involved in activation of nSMase2 are not well defined. TNFa has been shown to induce translocation of the enzyme to the plasma membrane, in a mechanism that depends on activation of p38 mitogen-activated protein kinase (MAPK)85. In confluent cells and tissue cells (hepatocytes), nSMase2 resides basally at the plasma membrane. Importantly, it appears to localize to the inner leaflet of the plasma membrane where, presumably, a minor pool of SM may reside90.
SK1–S1P in inflammation and angiogenesis. An overwhelming amount of primary literature has established the participation of the SK1–S1P–S1PR axis in multiple signalling pathways38,91. Many growth factors, such as epidermal growth factor and platelet-derived growth factor, as well as the cytokines TNFa and IL-1, activate SK1 acutely, resulting in transient elevations in the levels of S1P (usually 2–3 fold)25. This stimulation requires PKC92, phospholipase D (PLD)93 and/or the extracellular signal-regulated kinase (ERK) MAPKs, which act upstream of SK1 (Ref. 94). PKC may act directly or indirectly through PLD and ERK, whereas it has been proposed that ERK directly phosphorylates SK1 on residue Ser225 (Ref. 94), which is required for its translocation to the plasma membrane. PLD generates phosphatidic acid, which may directly bind SK1 and lead to its membrane association33.
S1P that is generated by this process has been detected predominantly in the extracellular space and, given its zwitterionic character, these results suggest the need for active transport mechanisms. Indeed, it has been proposed recently that the ABC transporter ABCC1 is required for transporting S1P from the inner leaflet of the plasma membrane to the cell exterior40. Alternatively, SK1 itself has also been detected extracellularly. Once outside the cell, S1P binds S1PRs with high affinity and launches typical GPCR signalling pathways95 (Fig. 6).
At the cellular level, the SK1–S1P pathway has been best studied in relation to cytokine action, with multiple functions related to the pro-inflammatory actions of TNFa (and IL-1). Within 10 minutes of stimulation with TNFa, SK1 is activated in a mechanism that is dependent on TRAF (TNFa receptor-associated factor) and ERK96. Knockdown studies have implicated SK1 in mediating the effects of TNFa on induction of cyclooxygenase-2 (COX2), the production of prostaglandins37,97, the induction of adhesion molecules98 and activation of eNOS83. Interestingly, knockdown of S1P phosphatase or S1P lyase (the key enzymes that metabolize S1P) augmented prostaglandin production, concomitant with augmentation of S1P levels37. This specifically indicates that S1P is the mediator of SK1 action and not subsequent metabolites.
At the organismal level, the SK1–S1P–S1P1R pathway has been clearly implicated in the regulation of angiogenesis because S1P1R is present at high levels on endothelial cells and is known to have important roles in angiogenesis; in addition, knockout of S1P1R results in embryonic lethality due to poor vascular development99. The combined knockout of SK1 and SK2 also recapitulated this phenotype100. Studies in endothelial and smooth muscle cells support key roles for S1P in regulating endothelial cell proliferation, migration and tube formation, and the activation of smooth muscle migration and proliferation101.
Furthermore, S1P1R along with S1P3R and S1P4R are enriched in lymphoid organs and have key roles in regulating lymphoid sequestration and/or egress from lymph nodes102. Recently, FTY270, a sphingosine analogue, was shown to be phosphorylated by SK2 and to act as a potent agonist of S1P receptors. FTY720 is currently in clinical studies for its roles in immune modulation (for example, in multiple sclerosis103), thus underscoring the importance of S1P in the regulation of lymphocyte function and immunity.
It is also important to remember that SK1 and SK2 serve a key metabolic function in the penultimate breakdown of all sphingolipids, whereby the irreversible breakdown of the product S1P leads to metabolic exit from the sphingolipid pathway. Thus, changes in SK activity may have long-term effects, not only on the levels of S1P but also on ceramide, complex sphingolipids and sphingoid bases. This is well demonstrated in siRNA studies that show the significant accumulation of ceramide in response to knockdown of SK1 (Ref. 104).
Conclusions and future directions
The above examples focus on specific, regulated sphingolipid pathways and enzymes that have been more extensively studied than other enzymes and pathways, such as SM synthases, ceramidases, ceramide synthases, GCS, CERT, S1P phosphatase and S1P lyase, which are currently subject to intensive investigation. Sphingolipids other than ceramide and S1P are emerging as candidate bioeffector molecules. These include C1P, which has roles in activation of phospholipase A2 (Refs 105,106), regulation of vesicular trafficking, phagocytosis10, macrophage degranulation9 and in mitogenesis107. Glucosylceramide has been implicated in resistance to chemotherapeutic agents12, and may serve as the endogenous cargo for the P-glycoprotein transporter MDR1 (Ref. 108). Dihydroceramide, which had been shown to be inactive in apoptosis, has been implicated in mediating the growth inhibitory actions of fenretinide (a retinoid analogue used in the treatment of neuroblastoma), which has been shown to inhibit the activity of the desaturase109,110,111. Lyso-sphingomyelin has been shown to induce multiple cellular effects, possibly mediated by binding to specific GPCRs112. These additional pathways and bioactive metabolites clearly represent areas of future investigation.
The examples described here highlight important roles for sphingoid bases, ceramide and S1P in regulation of the cell cycle, stress responses, pro-inflammatory pathways and cell migration, with key roles in apoptosis, inflammation and angiogenesis. These cellular roles extend to organismal function and pathobiology and have implications for the understanding of cancer biology, arthritis and inflammation, diabetes, immune function and neurodegenerative disorders113,114,115. Notwithstanding the many difficulties and complexities in studying bioactive lipids, these examples demonstrate the power of modern cell biology and biochemistry in elucidating these pathways through the use of knockout mice, siRNA technology, liquid chromatography–mass spectrometry-based 'lipidomic' analysis, confocal microscopy, chemical biology, mathematical modelling and systems biology approaches.
There are several take-home messages. First, this ever-enlarging spectrum of bioactive lipids has, in effect, reversed our assumptions about the putative functions of lipid metabolism and the roles of minor lipids. Past generations of investigators may have been sceptical of the significance of lipids in cell biology, but we are now at a point where one can almost assume that lipids, which have regulated levels, are 'bioactive until proven otherwise'. Second, it is clear that these pathways are now accessible to the cell biologist, provided that due attention is given to the peculiarities of bioactive lipids and their pathways, as discussed in this review. Third, sphingolipid-mediated pathways operate at the level of individual organelles, and thus should be studied as such. Functions of ceramide in the ER are clearly different from those at the plasma membrane; even in the membrane, ceramide seems to regulate different functions depending on whether it is formed at the inner or outer leaflet. Similar considerations may apply to SK1 and SK2 (Ref. 116). Fourth, the complexity of sphingolipid metabolism and the metabolic interconversion of bioactive sphingolipids provide the cell with an extremely rich repertoire for not only generating multiple signals, but also for fine-tuning specific responses. Therefore, the field of bioactive sphingolipids constitutes its own area of biological '-omics', the 'sphingolipidome'. This generates the anticipation that many modern analytical techniques and the mathematical approaches of systems biology will be brought to bear on this field, as has been trialled with modelling of the sphingolipid metabolic pathways of yeast117.
The study of bioactive lipids is only now coming to the forefront of cell biology, representing possibly one of the last frontiers in molecular cell biology. Clearly, more work is required to dissect each of the many regulated pathways of bioactive sphingolipids and define the mechanisms of regulation of enzymes, roles of the pathways in specific cell responses, and mechanisms by which individual bioactive sphingolipids, which act in specific subcellular compartments, mediate those actions.
References
Hokin, M. R. & Hokin, L. E. Enzyme secretion and the incorporation of 32P into phospholipids of pancreas slices. J. Biol. Chem. 203, 967–977 (1953). Earliest study to demonstrate agonist-induced turnover of inositol phospholipids.
Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258, 607–614 (1992). An excellent review, by a pioneer in the field on bioactive lipids, that discusses the discovery of activation of PKC by DAG.
Serhan, C. N. & Savill, J. Resolution of inflammation: the beginning programs the end. Nature Immunol. 6, 1191–1197 (2005).
Smith, E. R., Merrill, A. H., Obeid, L. M. & Hannun, Y. A. Effects of sphingosine and other sphingolipids on protein kinase C. Methods Enzymol. 312, 361–373 (2000).
Obeid, L. M., Linardic, C. M., Karolak, L. A. & Hannun, Y. A. Programmed cell death induced by ceramide. Science 259, 1769–1771 (1993). A landmark study that implicated ceramide in apoptosis.
Venable, M. E., Lee, J. Y., Smyth, M. J., Bielawska, A. & Obeid, L. M. Role of ceramide in cellular senescence. J. Biol. Chem. 270, 30701–30708 (1995). The first study to implicate ceramide in cellular senescence.
Hla, T. Physiological and pathological actions of sphingosine 1-phosphate. Semin. Cell Dev. Biol. 15, 513–520 (2004).
Chalfant, C. E. & Spiegel, S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J. Cell Sci. 118, 4605–4612 (2005).
Mitsutake, S. et al. Ceramide kinase is a mediator of calcium-dependent degranulation in mast cells. J. Biol. Chem. 279, 17570–17577 (2004).
Hinkovska-Galcheva, V. et al. Ceramide 1-phosphate, a mediator of phagocytosis. J. Biol. Chem. 280, 26612–26621 (2005).
Radin, N. S., Shayman, J.A. & Inokuchi, J.-I. Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances. Adv. Lipid Res. 26, 183–211 (1993).
Gouaze-Andersson, V. & Cabot, M. C. Glycosphingolipids and drug resistance. Biochim. Biophys. Acta 1758, 2096–2103 (2006).
Hannun, Y. A. & Obeid, L. M. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 277, 25847–25850 (2002).
Linn, S. C. et al. Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. Biochem. Soc. Trans. 29, 831–835 (2001).
Pewzner-Jung, Y., Ben-Dor, S. & Futerman, A. H. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: insights into the regulation of ceramide synthesis. J. Biol. Chem. 281, 25001–25005 (2006).
Causeret, C., Geeraert, L., Van der Hoeven, G., Mannaerts, G. P. & van Veldhoven, P. P. Further characterization of rat dihydroceramide desaturase: tissue distribution, subcellular localization, and substrate specificity. Lipids 35, 1117–1125 (2000).
Wijesinghe, D. S. et al. Substrate specificity of human ceramide kinase. J. Lipid Res. 46, 2706–2716 (2005).
Raas-Rothschild, A., Pankova-Kholmyansky, I., Kacher, Y. & Futerman, A. H. Glycosphingolipidoses: beyond the enzymatic defect. Glycoconj. J. 21, 295–304 (2004).
Tafesse, F. G., Ternes, P. & Holthuis, J. C. The multigenic sphingomyelin synthase family. J. Biol. Chem. 281, 29421–29425 (2006).
Hakomori, S. Traveling for the glycosphingolipid path. Glycoconj. J. 17, 627–647 (2000).
Ichikawa, S. & Hirabayashi, Y. Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol. 8, 198–202 (1998).
Marchesini, N. & Hannun, Y. A. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem. Cell Biol. 82, 27–44 (2004).
Xu, R. et al. Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P. FASEB J. 20, 1813–1825 (2006).
Galadari, S. et al. Identification of a novel amidase motif in neutral ceramidase. Biochem. J. 393, 687–695 (2006).
Hait, N. C., Oskeritzian, C. A., Paugh, S. W., Milstien, S. & Spiegel, S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta 1758, 2016–2026 (2006).
Johnson, K. R. et al. Role of human sphingosine-1-phosphate phosphatase 1 in the regulation of intra- and extracellular sphingosine-1-phosphate levels and cell viability. J. Biol. Chem. 278, 34541–34547 (2003).
Brindley, D. N. Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J. Cell Biochem. 92, 900–912 (2004).
Sigal, Y. J., McDermott, M. I. & Morris, A. J. Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions. Biochem. J. 387, 281–293 (2005).
Bandhuvula, P. & Saba, J. D. Sphingosine-1-phosphate lyase in immunity and cancer: silencing the siren. Trends Mol. Med. 13, 210–217 (2007).
Bielawski, J., Szulc, Z. M., Hannun, Y. A. & Bielawska, A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography–tandem mass spectrometry. Methods 39, 82–91 (2006).
Merrill, A. H. Jr, Sullards, M. C., Allegood, J. C., Kelly, S. & Wang, E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36, 207–224 (2005). A comprehensive and cutting-edge review on mass spectrometry methodology to analyse the sphingolipidome.
Romiti, E. et al. Characterization of sphingomyelinase activity released by thrombin-stimulated platelets. Mol. Cell. Biochem. 205, 75–81 (2000).
Delon, C. et al. Sphingosine kinase 1 is an intracellular effector of phosphatidic acid. J. Biol. Chem. 279, 44763–44774 (2004).
Lopez-Montero, I. et al. Rapid transbilayer movement of ceramides in phospholipid vesicles and in human erythrocytes. J. Biol. Chem. 280, 25811–25819 (2005).
Khan, W. A. et al. Use of D-erythro-sphingosine as a pharmacologic inhibitor of protein kinase C in human platelets. Biochem. J. 278, 387–392 (1991).
Xia, P. et al. Tumor necrosis factor-α induces adhesion molecule expression through the sphingosine kinase pathway. Proc. Natl Acad. Sci. USA 95, 14196–14201 (1998). An important study that first demonstrated the activation of sphingosine kinase by TNFα.
Pettus, B. J. et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α. FASEB J. 17, 1411–1421 (2003). An important study that implicates the SK1–S1P pathway in inflammation.
Hla, T., Lee, M. J., Ancellin, N., Paik, J. H. & Kluk, M. J. Lysophospholipids — receptor revelations. Science 294, 1875–1878 (2001).
Boujaoude, L. C. et al. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. J. Biol. Chem. 276, 35258–35264 (2001).
Mitra, P. et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc. Natl Acad. Sci. USA 103, 16394–16399 (2006).
Hanada, K. et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature 426, 803–809 (2003). A breakthrough study on the discovery of ceramide transfer protein.
Fugmann, T. et al. Regulation of secretory transport by protein kinase D-mediated phosphorylation of the ceramide transfer protein. J. Cell Biol. 178, 15–22 (2007).
Chalfant, C. E., Szulc, Z., Roddy, P., Bielawska, A. & Hannun, Y. A. The structural requirements for ceramide activation of serine–threonine protein phosphatases. J. Lipid Res. 45, 496–506 (2004).
Dbaibo, G. et al. Rb as a downstream target for a ceramide-dependent pathway of growth arrest. Proc. Natl Acad. Sci. USA 92, 1347–1351 (1995).
Lee, J. Y., Hannun, Y. A. & Obeid, L. M. Ceramide inactivates cellular protein kinase Cα. J. Biol. Chem. 271, 13169–13174 (1996).
Zhou, H. L., Summers, S. K., Birnbaum, M. J. & Pittman, R. N. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J. Biol. Chem. 273, 16568–16575 (1998).
Müller, G. et al. PKCζ is a molecular switch in signal transduction of TNF-α, bifunctionally regulated by ceramide and arachidonic acid. EMBO J. 14, 1961–1969 (1995).
Bourbon, N. A., Sandirasegarane, L. & Kester, M. Ceramide-induced inhibition of Akt is mediated through protein kinase Cζ: implications for growth arrest. J. Biol. Chem. 277, 3286–3292 (2002).
Zhang, Y. H. et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 89, 63–72 (1997).
Heinrich, M. et al. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ. 11, 550–563 (2004).
Wang, G. et al. Direct binding to ceramide activates protein kinase Cζ before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J. Biol. Chem. 280, 26415–26424 (2005).
Okajima, F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim. Biophys. Acta 1582, 132–137 (2002).
Lee, M. J. et al. Sphingosine-1-phosphate as a ligand for the G protein coupled receptor EDG-1. Science 279, 1552–1555 (1998). The first study to identify and characterize an S1P receptor.
Bose, R. et al. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82, 405–414 (1995). An important study implicating ceramide synthase in chemotherapy-induced apoptosis.
Perry, D. K. et al. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem. 275, 9078–9084 (2000).
Kroesen, B. J. et al. BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome. J. Biol. Chem. 278, 14723–14731 (2003).
Chalfant, C. E. et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J. Biol. Chem. 277, 12587–12595 (2002).
Merrill, A. H. Jr, Wang, E. & Mullins, R. E. Kinetics of long-chain (sphingoid) base biosynthesis in intact LM cells: effects of varying the extracellular concentrations of serine and fatty acid precursors of this pathway. Biochemistry 27, 340–345 (1988).
Cowart, L. A. & Hannun, Y. A. Selective substrate supply in the regulation of yeast de novo sphingolipid synthesis. J. Biol. Chem. 282, 12330–12340 (2007).
Dickson, R. C., Sumanasekera, C. & Lester, R. L. Functions and metabolism of sphingolipids in Saccharomyces cerevisiae. Prog. Lipid Res. 45, 447–465 (2006).
Chung, N., Mao, C., Heitman, J., Hannun, Y. A. & Obeid, L. M. Phytosphingosine as a specific inhibitor of growth and nutrient import in Saccharomyces cerevisiae. J. Biol. Chem. 276, 35614–35621 (2001).
Friant, S., Lombardi, R., Schmelzle, T., Hall, M. N. & Riezman, H. Sphingoid base signaling via Pkh kinases is required for endocytosis in yeast. EMBO J. 20, 6783–6792 (2001).
Meier, K. D., Deloche, O., Kajiwara, K., Funato, K. & Riezman, H. Sphingoid base is required for translation initiation during heat stress in Saccharomyces cerevisiae. Mol. Biol. Cell 17, 1164–1175 (2006).
Unger, R. H. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144, 5159–5165 (2003).
Holland, W. L. et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5, 167–179 (2007). An important study that implicates ceramide in insulin resistance.
Rotolo, J. A. et al. Caspase-dependent and -independent activation of acid sphingomyelinase signaling. J. Biol. Chem. 280, 26425–26434 (2005).
Lozano, J. et al. Cell autonomous apoptosis defects in acid sphingomyelinase knockout fibroblasts. J. Biol. Chem. 276, 442–448 (2001).
Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155–1159 (2003).
Zeidan, Y. H., Wu, B. X., Jenkins, R. W., Obeid, L. M. & Hannun, Y. A. A novel role for protein kinase Cδ-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury. FASEB J. 13 Aug 2007 (doi:10.1096/fj.07-8967com).
Grassme, H., Riehle, A., Wilker, B. & Gulbins, E. Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms. J. Biol. Chem. 280, 26256–26262 (2005).
Zeidan, Y. H. et al. Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-α-induced PGE2 production. J. Biol. Chem. 281, 24695–24703 (2006).
Zeidan, Y. H. & Hannun, Y. A. Activation of acid sphingomyelinase by protein kinase Cδ-mediated phosphorylation. J. Biol. Chem. 282, 11549–11561 (2007).
Lin, T. et al. Role of acidic sphingomyelinase in Fas/CD95-mediated cell death. J. Biol. Chem. 275, 8657–8663 (2000).
Nix, M. & Stoffel, W. Perturbation of membrane microdomains reduces mitogenic signaling and increases susceptibility to apoptosis after T cell receptor stimulation. Cell Death Differ. 7, 413–424 (2000).
Castillo, S. S., Levy, M., Thaikoottathil, J. V. & Goldkorn, T. Reactive nitrogen and oxygen species activate different sphingomyelinases to induce apoptosis in airway epithelial cells. Exp. Cell Res. 313, 2680–2686 (2007).
Becker, K. P., Kitatani, K., Idkowiak-Baldys, J., Bielawski, J. & Hannun, Y. A. Selective inhibition of juxtanuclear translocation of protein kinase C βII by a negative feedback mechanism involving ceramide formed from the salvage pathway. J. Biol. Chem. 280, 2606–2612 (2005).
Clarke, C. J. et al. The extended family of neutral sphingomyelinases. Biochemistry 45, 11247–11256 (2006).
Hofmann, K., Tomiuk, S., Wolff, G. & Stoffel, W. Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc. Natl Acad. Sci. USA 97, 5895–5900 (2000).
Marchesini, N., Luberto, C. & Hannun, Y. A. Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J. Biol. Chem. 278, 13775–13783 (2003).
Aubin, I. et al. A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse. Nature Genet. 37, 803–805 (2005).
Stoffel, W. et al. Neutral sphingomyelinase (SMPD3) deficiency causes a novel form of chondrodysplasia and dwarfism that is rescued by Col2A1-driven smpd3 transgene expression. Am. J. Pathol. 171, 153–161 (2007).
Karakashian, A. A., Giltiay, N. V., Smith, G. M. & Nikolova-Karakashian, M. N. Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-β-induced JNK activation. FASEB J. 18, 968–970 (2004).
De Palma, C., Meacci, E., Perrotta, C., Bruni, P. & Clementi, E. Endothelial nitric oxide synthase activation by tumor necrosis factor α through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler. Thromb. Vasc. Biol. 26, 99–105 (2006).
Rutkute, K., Karakashian, A. A., Giltiay, N. V., Dobierzewska, A. & Nikolova-Karakashian, M. N. Aging in rat causes hepatic hyperresponsiveness to interleukin-1β which is mediated by neutral sphingomyelinase-2. Hepatology 46, 1166–1176 (2007). A crucial study that demonstrates a role for ceramide and sphingomyelin in ageing in vivo.
Clarke, C. J., Truong, T. G. & Hannun, Y. A. Role for neutral sphingomyelinase-2 in tumor necrosis factor α-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J. Biol. Chem. 282, 1384–1396 (2007).
Grimm, M. O. et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nature Cell Biol. 7, 1118–1123 (2005).
Zeng, C. et al. Amyloid-β peptide enhances tumor necrosis factor-α-induced iNOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes. J. Neurochem. 94, 703–712 (2005).
Hayashi, Y., Kiyono, T., Fujita, M. & Ishibashi, M. cca1 is required for formation of growth-arrested confluent monolayer of rat 3Y1 cells. J. Biol. Chem. 272, 18082–18086 (1997).
Marchesini, N. et al. Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J. Biol. Chem. 279, 25101–25111 (2004).
Tani, M. & Hannun, Y. A. Analysis of membrane topology of neutral sphingomyelinase 2. FEBS Lett. 581, 1323–1328 (2007).
Spiegel, S. & Milstien, S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nature Rev. Mol. Cell Biol. 4, 397–407 (2003).
Johnson, K. R., Becker, K. P., Facchinetti, M. M., Hannun, Y. A. & Obeid, L. M. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J. Biol. Chem. 277, 35257–35262 (2002).
Melendez, A., Floto, R. A., Gillooly, D. J., Harnett, M. M. & Allen, J. M. FcγRI coupling to phospholipase D initiates sphingosine kinase-mediated calcium mobilization and vesicular trafficking. J. Biol. Chem. 273, 9393–9402 (1998).
Pitson, S. M. et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 22, 5491–5500 (2003).
Taha, T. A., Argraves, K. M. & Obeid, L. M. Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy. Biochim. Biophys. Acta 1682, 48–55 (2004).
Xia, P. et al. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-α signaling. J. Biol. Chem. 277, 7996–8003 (2002).
Billich, A. et al. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL-1β and TNF-α induced production of inflammatory mediators. Cell Signal. 17, 1203–1217 (2005).
Lee, M. J. et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99, 301–312 (1999).
Liu, Y. et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 106, 951–961 (2000).
Mizugishi, K. et al. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25, 11113–11121 (2005).
Peters, S. L. & Alewijnse, A. E. Sphingosine-1-phosphate signaling in the cardiovascular system. Curr. Opin. Pharmacol. 7, 186–192 (2007).
Rosen, H., Sanna, G. & Alfonso, C. Egress: a receptor-regulated step in lymphocyte trafficking. Immunol. Rev. 195, 160–177 (2003).
Gonsette, R. E. New immunosuppressants with potential implication in multiple sclerosis. J. Neurol. Sci. 223, 87–93 (2004).
Taha, T. A. et al. Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J. 20, 482–484 (2006).
Pettus, B. J. et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J. Biol. Chem. 279, 11320–11326 (2004).
Mitsutake, S. & Igarashi, Y. Calmodulin is involved in the Ca2+-dependent activation of ceramide kinase as a calcium sensor. J. Biol. Chem. 280, 40436–40441 (2005).
Gomez-Munoz, A. Ceramide 1-phosphate/ceramide, a switch between life and death. Biochim. Biophys. Acta 1758, 2049–2056 (2006).
Raggers, R. J., van Helvoort, A., Evers, R. & van Meer, G. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J. Cell Sci. 112, 415–422 (1999).
Schulz, A. et al. The CLN9 protein, a regulator of dihydroceramide synthase. J. Biol. Chem. 281, 2784–2794 (2006).
Kraveka, J. M. et al. Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J. Biol. Chem. 282, 16718–16728 (2007).
Zheng, W. et al. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim. Biophys. Acta 1758, 1864–1884 (2006).
Ignatov, A. et al. Role of the G-protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development. J. Neurosci. 23, 907–914 (2003).
Zeidan, Y. H. & Hannun, Y. A. Translational aspects of sphingolipid metabolism. Trends Mol. Med. 13, 327–336 (2007).
Radin, N. S. Designing anticancer drugs via the achilles heel: ceramide, allylic ketones, and mitochondria. Bioorg. Med. Chem. 11, 2123–2142 (2003).
Summers, S. A. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45, 42–72 (2006).
Wattenberg, B. W., Pitson, S. M. & Raben, D. M. The sphingosine and diacylglycerol kinase superfamily of signaling kinases: localization as a key to signaling function. J. Lipid Res. 47, 1128–1139 (2006).
Alvarez-Vasquez, F. et al. Simulation and validation of modelled sphingolipid metabolism in Saccharomyces cerevisiae. Nature 433, 425–430 (2005).
D'Angelo, G. et al. Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature 449, 62–67 (2007).
Acknowledgements
We would like to thank all past and present members of our laboratories. This work was supported by a Veterans Affairs Merit Award (L.M.O.) and the National Institutes of Health (Y.A.H.).
Author information
Authors and Affiliations
Related links
Related links
DATABASES
OMIM
FURTHER INFORMATION
Glossary
- DAG
-
sn-1,2-diacylglycerol is a key metabolic intermediate in glycerolipid synthesis that also serves as a second messenger in regulating classical and novel protein kinase C enzymes.
- Protein kinase C
-
(PKC). A family of closely related protein kinases that are highly conserved in their catalytic domains. Classical PKCs are regulated by diacylglycerol (DAG) and calcium; novel PKCs are regulated by DAG only; and atypical PKCs are not regulated by either DAG or calcium.
- Ceramide synthase
-
(CerS, Lass). An enzyme that introduces the acyl chain to sphingoid bases, thereby forming dihydroceramides and ceramides with specific N-linked fatty acids.
- Acid SMase
-
A sphingomyelinase enzyme with an acid pH optimum that removes the phosphorylcholine head group from sphingomyelin, generating ceramide (or dihydroceramides). Activity is defective in patients with type A or B Niemann–Pick disease.
- Neutral SMase
-
(nSMases). An emerging family of sphingomyelinase enzymes with a neutral pH optimum that removes the phosphorylcholine head group from sphingomyelin, generating ceramide (or dihydroceramides).
- Ceramidase
-
A hydrolase that removes the fatty acyl groups from ceramides and dihydroceramides. Three distinct enzyme families are recognized on the basis of their pH optima (acid, neutral and alkaline).
- Glycosphingolipid
-
A complex sphingolipid with a carbohydrate head group that is attached to the 1-hydroxy group of ceramide. The simplest glycosphingolipids are glucosylceramide and galactosylceramide with a glucose or galactose group, respectively, from which more complex glycosphingolipids can be synthesized by the incorporation of additional glycose subunits.
- Salvage pathway
-
In addition to de novo synthesis, sphingolipids can be resynthesized following the breakdown of complex sphingolipids (mostly in the lysosome) through the re-incorporation of the liberated sphingosine into ceramide.
- ABC transporter superfamily
-
A family of membrane proteins that regulate the transport of small molecules in an ATP-dependent process.
- Ceramide transfer protein
-
(CERT). Belongs to a family of lipid transporters, and selectively transports ceramide from its site of synthesis in the ER to the site of sphingomyelin biosynthesis in the Golgi.
Rights and permissions
About this article
Cite this article
Hannun, Y., Obeid, L. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9, 139–150 (2008). https://doi.org/10.1038/nrm2329
Issue Date:
DOI: https://doi.org/10.1038/nrm2329
This article is cited by
-
Sphingolipids: drivers of cardiac fibrosis and atrial fibrillation
Journal of Molecular Medicine (2024)
-
Ionic composition of Shotokuseki extract alters cell differentiation and lipid metabolism in three-dimensional cultured human epidermis
Cytotechnology (2024)
-
Density of Sphingosine-1-Phosphate Receptors Is Altered in Cortical Nerve-Terminals of Insulin-Resistant Goto-Kakizaki Rats and Diet-Induced Obese Mice
Neurochemical Research (2024)
-
GIMAP5 deficiency reveals a mammalian ceramide-driven longevity assurance pathway
Nature Immunology (2024)
-
Gut microbiota combined with fecal metabolomics reveals the effects of FuFang Runzaoling on the microbial and metabolic profiles in NOD mouse model of Sjögren’s syndrome
BMC Complementary Medicine and Therapies (2023)